Alliance Global Partners lowered the firm’s price target on Verastem (VSTM) to $14 from $20 and keeps a Buy rating on the shares. In its updated sum-of-the-parts analysis, the firm values avutometinib for LGSOC at $13.25 per share, and attributes 75c per share in value for the company’s technology and cash net of debt.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem cuts FY24 EPS view to $4.17-$4.23 from $4.25-$4.35, consensus $4.28
- Verastem reports Q3 EPS (60c), consensus (74c)
- Verastem completes rolling NDA submission to FDA for Avutometinib+Defactinib
- VSTM Earnings this Week: How Will it Perform?
- Truist remains bullish on Verastem, says weakness in shares ‘an overreaction’